---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-144484"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:46:39.105967+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Crinetics announces early release of ENDO 2024 late-breaking abstracts for atumelnant Phase 2 CAH study

## Summary
- Late-breaking abstracts for atumelnant (CRN04894) Phase 2 CAH study released before embargo.
- Abstract contained summary data on 4 subjects; data from 6 subjects in cohort 1 and cohort 2 to be presented June 3, 2024.
- Full data set will be presented at ENDO 2024 poster session on June 1-2 pm ET.

## SEC filing metadata
- accession: 0001193125-24-144484
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312524144484/0001193125-24-144484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312524144484/d815433d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-144484
- JSON: https://secwatch.observer/filing/0001193125-24-144484.json
- Plain text: https://secwatch.observer/filing/0001193125-24-144484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.